Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — Corporate Update (September 2021)
21 slides from Scopus Biopharma's corporate update, Sep 13, 2021
Slide 1: Launch of Duet Therapeutics, a wholly-owned immuno-oncology subsidiary of Scopus BioPharma
Launch of Duet Therapeutics, a wholly - owned immuno - oncology subsidiary of Scopus BioPharma September 2021
Slide 2: Disclaimers
DISCLAIMERS This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . All statements regarding Scopus BioPharma Inc . , “Scopus” or the “Company” that are not historical fact, including, but not limited to, statements regardi
Slide 3: Scopus BioPharma at a Glance
SCOPUS BIOPHARMA AT A GLANCE Scopus is a clinical - stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need COMPANY EXCHANGE SYMBOL SHARE PRICE MARKET CAP 10 - DAY AVG VOLUME SHARES OUTSTANDING Scopus BioPharma NASDAQ Global M
Slide 4: Duet Therapeutics, a Scopus BioPharma Company
DUET THERAPEUTICS, A SCOPUS BIOPHARMA COMPANY A Scopus BioPharma company On September 2, 2021, Scopus announced the launch of Duet Therapeutics to integrate the management and clinical development of the immuno - oncology assets of Scopus and Olimmune, acquired by Scopus in June 2021
Slide 5: Creating targeted oligonucleotide therapies for treatment-resistant cancers
A Scopus BioPharma company Creating targeted oligonucleotide therapies for treatment - resistant cancers
Slide 6: Investment highlights
Investment highlights 6 Duet’s platform provides a unique approach to treating hematological malignancies and solid tumor cancers Strong IP position Duet has 4 issued patents and 4 submitted PCT applications that cover the technologies that make up Duet’s platform. Bi - functional mode of action Due
Slide 7: Technology portfolio
Technology portfolio 7 The Duet technologies create a powerful portfolio of bi - functional molecules that hold broad potential across multiple tumor types Molecule name CpG - STAT3siRNA (DUET - 01) CpG - STAT3ASO (DUET - 02) CpG - STAT3decoy (DUET - 03) Structure STAT3 mechanism of action Bi - func
Slide 8: Duet pipeline
Duet pipeline 8 Duet’s pipeline of STAT3 inhibitors includes a suite of technologies and several expansion indications in immuno - oncology Candidate Program / indication Discovery / optimization IND enabling Phase 1 Development DUET - 01 B - cell non - Hodgkin lymphoma DUET - 01 + ICI B - cell non
Slide 9: The problem
The problem 9 Tumor cells co - opt the immune system to evade adaptive immunity and promote oncogenesis in the TME Tumors use checkpoints to evade immune response and block activity of cytotoxic T cells and NK cells 2 Tumors recruit T reg and immature myeloid cells to create an immunosuppressive env
Slide 10: STAT3 as an I-O target
STAT3 as an I - O target 10 STAT3 is a master regulator of the immune system and a high - value immuno - oncology target, but requires cell - specific modulation Tumor cell STAT3 • Immune evasion • Proliferation • Angiogenesis • Metastasis STAT3 plays a major role in maintaining immunosuppression in
Slide 11: The Duet solution
The Duet solution 11 Duet strategy: bi - functional oligonucleotide activates immune system (TLR9) and turns off master checkpoint (STAT3) Scavenger receptors, highly expressed in antigen - presenting cells, have a natural affinity for phosphorothioated CpG oligos, leading to rapid uptake of Duet’s
Slide 12: siRNA for B-cell NHL
siRNA for B - cell NHL 12 DUET - 01 targets TLR9 + immune cells and results in complete response in A20 model of B - cell non - Hodgkin lymphoma Zhang et al. , TLR9 - mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo, Blood (2013) 1 Targeted uptake of DU
Slide 13: Phase 1 clinical trial
Phase 1 clinical trial 13 A Phase I study of intratumoral injections of DUET - 01 with local radiation in patients with relapsed/refractory B - cell NHL ELIZABETH BUDDE, MD, PHD Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope P
Slide 14: Phase 1 clinical trial dose levels
Phase 1 clinical trial 14 The Phase 1 clinical trial is evaluating three different dose levels of DUET - 01 in combination with radiation therapy for B cell NHL DLT assessment 1 2 3 4 5 9 11 16 18 19 23 25 42 56 Primary tumor site Secondary tumor sites Peripheral blood draw Radiation (200 cGy ) CpG
Slide 15: ASO for prostate cancer
ASO for prostate cancer 15 DUET - 02 restores human T - cell proliferation and activity in the prostate tumor microenvironment Moreira et al. , STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration - resistant prostate cancers,
Slide 16: ASO for prostate cancer: T-cell mediated rejection
ASO for prostate cancer 16 DUET - 02 induces T - cell mediated rejection of bone - localized and ICI - resistant prostate cancers in mice Six intravenous injections of DUET - 02 are sufficient to unleash potent antitumor effects and increase animal survival in genetically different prostate tumor mo
Slide 17: ASO for head & neck cancer
ASO for head & neck cancer 17 DUET - 02 generates effective CD8 + T - cell immune responses against human HPV - head and neck cancer (HNC) in humanized mice CpG - STAT3ASO (DUET - 02) results in regression of xenotransplanted human head and neck tumors (SCC1) in humanized mice, with evidence of immu
Slide 18: Planned clinical trials
Planned clinical trials 18 Duet is planning two clinical Phase 1 trials to begin in Q1 2023 for Genitourinary and Head & Neck Cancers Genitourinary Cancers Tanya Dorff MD Associate Clinical Professor, Medical Oncology & Therapeutics Research, Head of the Genitourinary Cancers Program at City of Hope
Slide 19: Timeline & milestones
Target milestones that will culminate in Phase 1 clinical trials in three unique clinical indications Q3 2021 Q1 2022 Q3 2022 Q1 2023 Q4 2021 Q2 2022 Q4 2022 • Launch of Duet Therapeutics through Scopus/Olimmune integration • Completion of GMP manufacturing for IND - enabling studies for DUET - 02 •
Slide 20: Leadership team
20 ALAN HORSAGER, PH.D. President, CEO & Director Duet is building a leadership team that has extensive company building and clinical development experience MARCIN KORTYLEWSKI, PH.D. Senior Scientific Advisor Other team members to be announced in the coming weeks Leadership team
Slide 21: Contact
Contact Alan Horsager, Ph.D. President – Immuno - Oncology, Scopus BioPharma President & CEO, Duet Therapeutics horsager@duettx.com A Scopus BioPharma company